Cargando…

COVID-19 vaccine safety inquiries to the centers for disease control and prevention immunization safety office

BACKGROUND: Following the authorization and recommendations for use of the U.S. COVID-19 vaccines, the Centers for Disease Control and Prevention (CDC)’s Immunization Safety Office (ISO) responded to inquiries and questions from public health officials, healthcare providers, and the general public o...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, Elaine R., Moro, Pedro L., Shimabukuro, Tom T., Carlock, Grace, Davis, Shaeyla N., Freeborn, Emma M., Roberts, Amy L., Gee, Julianne, Taylor, Allan W., Gallego, Ruth, Suragh, Tiffany, Su, John R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208263/
https://www.ncbi.nlm.nih.gov/pubmed/37248099
http://dx.doi.org/10.1016/j.vaccine.2023.05.054
_version_ 1785046631175946240
author Miller, Elaine R.
Moro, Pedro L.
Shimabukuro, Tom T.
Carlock, Grace
Davis, Shaeyla N.
Freeborn, Emma M.
Roberts, Amy L.
Gee, Julianne
Taylor, Allan W.
Gallego, Ruth
Suragh, Tiffany
Su, John R.
author_facet Miller, Elaine R.
Moro, Pedro L.
Shimabukuro, Tom T.
Carlock, Grace
Davis, Shaeyla N.
Freeborn, Emma M.
Roberts, Amy L.
Gee, Julianne
Taylor, Allan W.
Gallego, Ruth
Suragh, Tiffany
Su, John R.
author_sort Miller, Elaine R.
collection PubMed
description BACKGROUND: Following the authorization and recommendations for use of the U.S. COVID-19 vaccines, the Centers for Disease Control and Prevention (CDC)’s Immunization Safety Office (ISO) responded to inquiries and questions from public health officials, healthcare providers, and the general public on COVID-19 vaccine safety. METHODS: We describe COVID-19 vaccine safety inquiries, by topic, received and addressed by ISO from December 1, 2020–August 31, 2022. RESULTS: Of the 1978 COVID-19 vaccine-related inquiries received, 1655 specifically involved vaccine safety topics. The most frequently asked-about topics included deaths following vaccination, myocarditis, pregnancy, and reproductive health outcomes, understanding or interpreting data from the Vaccine Adverse Event Reporting System (VAERS), and thrombosis with thrombocytopenia syndrome. CONCLUSIONS: Inquiries about vaccine safety generally reflect issues that receive media attention. ISO will continue to monitor vaccine safety inquiries and provide accurate and timely information to healthcare providers, public health officials, and the general public.
format Online
Article
Text
id pubmed-10208263
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier Science
record_format MEDLINE/PubMed
spelling pubmed-102082632023-05-25 COVID-19 vaccine safety inquiries to the centers for disease control and prevention immunization safety office Miller, Elaine R. Moro, Pedro L. Shimabukuro, Tom T. Carlock, Grace Davis, Shaeyla N. Freeborn, Emma M. Roberts, Amy L. Gee, Julianne Taylor, Allan W. Gallego, Ruth Suragh, Tiffany Su, John R. Vaccine Short Communication BACKGROUND: Following the authorization and recommendations for use of the U.S. COVID-19 vaccines, the Centers for Disease Control and Prevention (CDC)’s Immunization Safety Office (ISO) responded to inquiries and questions from public health officials, healthcare providers, and the general public on COVID-19 vaccine safety. METHODS: We describe COVID-19 vaccine safety inquiries, by topic, received and addressed by ISO from December 1, 2020–August 31, 2022. RESULTS: Of the 1978 COVID-19 vaccine-related inquiries received, 1655 specifically involved vaccine safety topics. The most frequently asked-about topics included deaths following vaccination, myocarditis, pregnancy, and reproductive health outcomes, understanding or interpreting data from the Vaccine Adverse Event Reporting System (VAERS), and thrombosis with thrombocytopenia syndrome. CONCLUSIONS: Inquiries about vaccine safety generally reflect issues that receive media attention. ISO will continue to monitor vaccine safety inquiries and provide accurate and timely information to healthcare providers, public health officials, and the general public. Elsevier Science 2023-06-19 2023-05-24 /pmc/articles/PMC10208263/ /pubmed/37248099 http://dx.doi.org/10.1016/j.vaccine.2023.05.054 Text en Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Short Communication
Miller, Elaine R.
Moro, Pedro L.
Shimabukuro, Tom T.
Carlock, Grace
Davis, Shaeyla N.
Freeborn, Emma M.
Roberts, Amy L.
Gee, Julianne
Taylor, Allan W.
Gallego, Ruth
Suragh, Tiffany
Su, John R.
COVID-19 vaccine safety inquiries to the centers for disease control and prevention immunization safety office
title COVID-19 vaccine safety inquiries to the centers for disease control and prevention immunization safety office
title_full COVID-19 vaccine safety inquiries to the centers for disease control and prevention immunization safety office
title_fullStr COVID-19 vaccine safety inquiries to the centers for disease control and prevention immunization safety office
title_full_unstemmed COVID-19 vaccine safety inquiries to the centers for disease control and prevention immunization safety office
title_short COVID-19 vaccine safety inquiries to the centers for disease control and prevention immunization safety office
title_sort covid-19 vaccine safety inquiries to the centers for disease control and prevention immunization safety office
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208263/
https://www.ncbi.nlm.nih.gov/pubmed/37248099
http://dx.doi.org/10.1016/j.vaccine.2023.05.054
work_keys_str_mv AT millerelainer covid19vaccinesafetyinquiriestothecentersfordiseasecontrolandpreventionimmunizationsafetyoffice
AT moropedrol covid19vaccinesafetyinquiriestothecentersfordiseasecontrolandpreventionimmunizationsafetyoffice
AT shimabukurotomt covid19vaccinesafetyinquiriestothecentersfordiseasecontrolandpreventionimmunizationsafetyoffice
AT carlockgrace covid19vaccinesafetyinquiriestothecentersfordiseasecontrolandpreventionimmunizationsafetyoffice
AT davisshaeylan covid19vaccinesafetyinquiriestothecentersfordiseasecontrolandpreventionimmunizationsafetyoffice
AT freebornemmam covid19vaccinesafetyinquiriestothecentersfordiseasecontrolandpreventionimmunizationsafetyoffice
AT robertsamyl covid19vaccinesafetyinquiriestothecentersfordiseasecontrolandpreventionimmunizationsafetyoffice
AT geejulianne covid19vaccinesafetyinquiriestothecentersfordiseasecontrolandpreventionimmunizationsafetyoffice
AT taylorallanw covid19vaccinesafetyinquiriestothecentersfordiseasecontrolandpreventionimmunizationsafetyoffice
AT gallegoruth covid19vaccinesafetyinquiriestothecentersfordiseasecontrolandpreventionimmunizationsafetyoffice
AT suraghtiffany covid19vaccinesafetyinquiriestothecentersfordiseasecontrolandpreventionimmunizationsafetyoffice
AT sujohnr covid19vaccinesafetyinquiriestothecentersfordiseasecontrolandpreventionimmunizationsafetyoffice